- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 86,300 | 17.06.24 08:02:05 | -0,400 | -0,46% | 87,100 | 87,500 | 86,300 | 86,700 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 967,800 | 17.06.24 08:10:52 | +15,000 | +1,57% | 967,800 | 975,200 | 967,800 | 952,800 |
